Avidity Biosciences to Present Oral Presentation on AOC 1001 for DM1 at American Academy of Neurology (AAN) 2021 Virtual Annual Meeting
News provided by
Share this article
Share this article
LA JOLLA, Calif., April 16, 2021 /PRNewswire/ Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs
™), today announced that preclinical data for their lead candidate, AOC 1001 in development for myotonic dystrophy type 1 (DM1), will be presented at the American Academy of Neurology (AAN) 2021 Virtual Annual Meeting being held April 17-22, 2021.
The abstract on AOC 1001 was chosen by the AAN Science Committee as one of 11 abstracts to be highlighted in the Emerging Science Session.